Substance Name: Nivolumab [USAN:INN]
RN: 946414-94-4
UNII: 31YO63LBSN

A genetically engineered, fully human immunoglobulin G4 (IgG4) monoclonal anti programmed death-1/PD-1 protein antibody.

A genetically engineered, fully human immunoglobulin G4 (IgG4) monoclonal anti programmed death-1/PD-1 protein antibody.

NCI: A fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation. (NCI Thesaurus)

C6362-H9862-N1712-O1995-S42

Unspecified